


## Thalidomide-NH-PEG2-COOH

<b>Cat. No.:</b>	HY-138772
<b>CAS No.:</b>	2412056-45-0
<b>Molecular Formula:</b>	C <sub>20</sub> H <sub>23</sub> N <sub>3</sub> O <sub>8</sub>
<b>Molecular Weight:</b>	433.41
<b>Target:</b>	E3 Ligase Ligand-Linker Conjugates
<b>Pathway:</b>	PROTAC
<b>Storage:</b>	-20°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 125 mg/mL (288.41 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.3073 mL	11.5364 mL	23.0728 mL
5 mM	0.4615 mL	2.3073 mL	4.6146 mL
10 mM	0.2307 mL	1.1536 mL	2.3073 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Thalidomide-NH-PEG2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	Cereblon
<b>In Vitro</b>	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine. *Front Cell Dev Biol.* 2021;9:629326. Published 2021 Mar 11.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA